This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Kalaris Therapeutics Presents TH103 Data
Tech clinical trial data presentation

Kalaris Therapeutics Presents TH103 Data

Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
20
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentation of positive Phase 1a clinical data for TH103 by AirNexis Therapeutics could lead to increased investor confidence and a potential rise in the company's stock price. This event highlights progress in addressing Neovascular Age-Related Macular Degeneration, a significant market for new treatments.

Biotechnology Pharmaceuticals
Event Summary

AirNexis Therapeutics, a clinical-stage biopharmaceutical company, is set to present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026 on June 13, 2026. The presentation will focus on single ascending dose results from treatment-na ve patients with Neovascular Age-Related Macular Degeneration (nAMD). TH103, engineered by Dr. Napoleone Ferrara, is an investigational dual-targeting biologic designed for intravitreal delivery with potential applications for various retinal diseases. Karl Csaky will be the speaker for this presentation. This event follows a recent presentation of the same data at Retina World Congress 2026.

Entities Involved
priv
AirNexis Therapeutics
AirNexis Therapeutics is presenting Phase 1a clinical data for its lead asset, TH103, which could positively impact its stock price and future development.
Importance 100.0 Sentiment 20.0
oth
TH103
TH103 is the lead asset of AirNexis Therapeutics, and the presentation of its Phase 1a clinical data is a significant step in its development as a treatment for retinal diseases.
Importance 90.0 Sentiment 20.0
oth
Neovascular age-related macular degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is the disease TH103 aims to treat, and the clinical data presentation is a step towards addressing this significant medical need.
Importance 70.0 Sentiment 10.0
per
Karl Csaky
Karl Csaky is the speaker presenting the clinical data for TH103 at the conference, lending scientific credibility to the presentation.
Importance 30.0 Sentiment 10.0
per
Napoleone Ferrara
Napoleone Ferrara founded AirNexis Therapeutics and engineered TH103, highlighting his foundational role in the company's research and development.
Importance 30.0 Sentiment 10.0
priv
LifeSci Advisors
LifeSci Advisors is the investor contact for AirNexis Therapeutics, facilitating communication with investors.
Importance 10.0 Sentiment 0.0
index
Nasdaq-100
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.